分组1 - Illumina reported quarterly earnings of $1.35 per share, exceeding the Zacks Consensus Estimate of $1.26 per share, and showing an increase from $0.86 per share a year ago, resulting in an earnings surprise of +7.42% [1] - The company achieved revenues of $1.16 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.35% and increasing from $1.1 billion year-over-year [2] - Illumina has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 2.3% since the beginning of the year, outperforming the S&P 500, which has gained 0.5% [3] - The future performance of Illumina's stock will depend on management's commentary during the earnings call and the earnings outlook for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $1.11 on revenues of $1.07 billion, and for the current fiscal year, it is $5.08 on revenues of $4.44 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Illumina belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8] - The correlation between near-term stock movements and earnings estimate revisions is strong, indicating that tracking these revisions can be beneficial for investors [5]

Financial Data and Key Metrics Changes - Illumina reported Q4 revenue of $1.16 billion, up 5% year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [26] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with 11% growth excluding China [22] - Research and applied markets consumable sales were roughly flat year-over-year, reflecting ongoing uncertainty in the funding environment [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, representing a $25 million decline from Q4 of 2024 [22] - Clinical market maintained momentum, growing 20% outside of China, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew at a rate of more than 30% year-over-year, primarily from clinical customers [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][13] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid-to-high single digits [30][31] - Management highlighted the importance of adapting to the evolving market dynamics and customer needs, particularly in the clinical space [16][70] Other Important Information - Illumina returned approximately $740 million to shareholders through share repurchases in 2025 [7] - The company ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The acquisition of SomaLogic was completed for an upfront payment of $350 million, with potential royalties and milestone payments [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and discussed capital deployment priorities [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of NovaSeq X placements were to clinical customers, with expectations for this trend to continue [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various diseases [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and the ability to address market segments with different pricing strategies [74][76] Question: China market assumptions and BioInsight monetization - Management discussed ongoing conversations with Chinese regulators and the potential for growth in the BioInsight business, emphasizing its early-stage momentum [80][81]

Financial Data and Key Metrics Changes - Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, reflecting a 42% year-over-year growth [26] - Non-GAAP operating margin expanded to 23.7%, up 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% in Q4 2025, excluding China, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue reached $755 million, an 8% increase year-over-year [22] - Research and applied markets consumable sales were roughly flat year-over-year, indicating a stabilization compared to previous quarters [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting ongoing export restrictions [22] - Clinical market growth outside of China was 20%, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew over 30% year-over-year, primarily from clinical applications [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [11][12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [30][31] - Management highlighted the importance of adapting to the evolving funding environment in the research sector [44] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [7] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The company plans to continue share repurchases opportunistically, with $643 million remaining on its authorization [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth momentum [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various applications [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and highlighted ongoing discussions with customers regarding pricing and workflow efficiencies [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Illumina's revenue reached $1.16 billion, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on a constant currency basis [18][19] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [24] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [23] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [4][19] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with a notable 11% increase excluding China [19] - Sequencing instruments revenue was approximately flat year-over-year at $154 million, with strong placements of NovaSeq X [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting export restrictions [19] - Clinical market outside China grew 20%, driven by broader adoption of NGS-based testing [19] - Research and applied markets saw consumable sales remain roughly flat year-over-year, indicating ongoing uncertainty in the funding environment [20] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [9][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities to accelerate innovation [10][11] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in the second half of 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [15][27] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [15][29] - Management highlighted the importance of adapting to evolving market dynamics and customer needs, particularly in the context of multi-omics [14][78] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [5] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents, maintaining a strong balance sheet [25] - The company plans to change geographical reporting segments starting in Q1 2026 to better align with its commercial structure [31] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [33][36] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects continued momentum in clinical growth, with expectations for mid-teens growth, while acknowledging challenges in the research environment [40][42] Question: Instrumentation split between research and clinical - Over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [46][48] Question: Growth drivers in oncology and genetic applications - Oncology is expected to remain the main growth driver, with significant uptake in genetic profiling for various diseases [62][64] Question: BioInsight monetization strategy - Management outlined plans for monetizing BioInsight through specialized data and subscription-based models, indicating a multi-year opportunity [78][79]

Q4 2025 Earnings Presentation February 5, 2026 © 2026 Illumina, Inc. All rights reserved. Cautionary Notes Year-over-year (YoY) denotes a comparison against the same quarter of the previous fiscal year, while quarter-over-quarter (QoQ) or "sequential" denotes a comparison against the previous fiscal quarter. In addition, all references to China refer to our Greater China Region, which also includes Taiwan and Hong Kong. © 2026 Illumina, Inc. All rights reserved. 2 RGB: 229, 96, 0 RGB: 228, 189, 255 RGB: 255 ...

Consolidated Balance Sheets(In millions)December 28,2025December 29,2024ASSETS(unaudited)Current assets:Cash and cash equivalents$ 1,418$ 1,127Short-term investments21593Accounts receivable, net854735Inventory, net564547Prepaid expenses and other current assets238244Total current assets3,2892,746Property and equipment, net759815Operating lease right-of-use assets370419Goodwill1,1131,113Intangible assets, net210295Deferred tax assets, net454567Other assets449348Total assets$ 6,644$ 6,303LIABILITIES AND STOCK ...

The upcoming report from Illumina (ILMN) is expected to reveal quarterly earnings of $1.26 per share, indicating an increase of 46.5% compared to the year-ago period. Analysts forecast revenues of $1.16 billion, representing an increase of 4.6% year over year.The consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a ...

Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity with the latest multiomic technologies SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from t ...

Key Takeaways Illumina reports Q4 results on Feb. 5, with EPS estimated at $1.26, up 46.5% YoY.Illumina's NovaSeq X and MiSeq i100 adoption likely boosted high and low-throughput sequencing revenues.New multiomic products and strategic partnerships may have further supported Illumina's Q4 revenues.Illumina, Inc. (ILMN) is set to release fourth-quarter 2025 results on Feb. 5, after the closing bell.The company posted adjusted earnings per share (EPS) of $1.34 in the last reported quarter, which surpassed the ...

此次整合标志着多组学研究新时代的开启，生物医学研究有望迎来新的发展机遇。 摘要 ： 基因测序巨头斥资3.5亿美元将蛋白质组学技术领导者纳入麾下，旨在为客户提供更全面的多 组学解决方案。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 美国加利福尼亚州圣迭戈——2026年1月30日，因美纳公司宣布已完成对蛋白质组学技术领 域领先企业SomaLogic的收购。此次交易总价值达3.5亿美元，另加高达7500万美元的绩效 里程碑款项。 这 一 收 购 标 志 着 因 美 纳 在 实 施 2024 年 提 出 的 多 组 学 战 略 过 程 中 取 得 重 要 进 展 。 通 过 整 合 SomaLogic高度差异化的蛋白质组学技术，因美纳将增强在基因组学与蛋白质组学领域提供 可扩展洞察的能力。 因美纳首席执行官Jacob Thay sen表示："欢迎SomaLogic团队加入因美纳，这是我们落实 2024年制定的多组学战略 的重要里程碑。" 此前，在2025年6月宣布收购协议时，因美纳曾表示预计该业务将在2027年实现非GAAP的 经营收入盈利。 ...